Synchroneuron is a privately held life science company based in the Boston area. The company is engaged in developing a novel treatment for movement disorders, utilizing a drug with simultaneous effects on excitatory and inhibitory neurotransmission.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/07/12 | $6,000,000 | Series A |
Accellient Partners Morningside Group | undisclosed |
| 07/02/14 | $20,000,000 | Series B |
Morningside Group | undisclosed |
